WO2006030439A3 - Compositions et methodes d'induction de la croissance capillaire - Google Patents

Compositions et methodes d'induction de la croissance capillaire Download PDF

Info

Publication number
WO2006030439A3
WO2006030439A3 PCT/IL2005/000991 IL2005000991W WO2006030439A3 WO 2006030439 A3 WO2006030439 A3 WO 2006030439A3 IL 2005000991 W IL2005000991 W IL 2005000991W WO 2006030439 A3 WO2006030439 A3 WO 2006030439A3
Authority
WO
WIPO (PCT)
Prior art keywords
hair growth
methods
compositions
inducing hair
inducing
Prior art date
Application number
PCT/IL2005/000991
Other languages
English (en)
Other versions
WO2006030439A2 (fr
Inventor
Michael Albeck
Benjamin Sredni
Original Assignee
Biomas Ltd
Michael Albeck
Benjamin Sredni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomas Ltd, Michael Albeck, Benjamin Sredni filed Critical Biomas Ltd
Priority to US11/662,743 priority Critical patent/US20090269418A1/en
Priority to JP2007531953A priority patent/JP2008513439A/ja
Priority to CA002580804A priority patent/CA2580804A1/fr
Priority to EP05784166A priority patent/EP1802292A4/fr
Priority to AU2005283719A priority patent/AU2005283719A1/en
Publication of WO2006030439A2 publication Critical patent/WO2006030439A2/fr
Publication of WO2006030439A3 publication Critical patent/WO2006030439A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C395/00—Compounds containing tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)

Abstract

L'invention concerne de nouvelles méthodes thérapeutiques et des compositions pharmaceutiques dans lesquelles sont utilisés des composés contenant du tellure pour induire la croissance capillaire dans le traitement de divers types d'alopécie et d'autres état associés à la chute des cheveux.
PCT/IL2005/000991 2004-09-17 2005-09-15 Compositions et methodes d'induction de la croissance capillaire WO2006030439A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/662,743 US20090269418A1 (en) 2004-09-17 2005-09-15 Compositions and Methods for Inducing Hair Growth
JP2007531953A JP2008513439A (ja) 2004-09-17 2005-09-15 発毛を誘導するための組成物および方法
CA002580804A CA2580804A1 (fr) 2004-09-17 2005-09-15 Compositions et methodes d'induction de la croissance capillaire
EP05784166A EP1802292A4 (fr) 2004-09-17 2005-09-15 Compositions et methodes d'induction de la croissance capillaire
AU2005283719A AU2005283719A1 (en) 2004-09-17 2005-09-15 Compositions and methods for inducing hair growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61066004P 2004-09-17 2004-09-17
US60/610,660 2004-09-17

Publications (2)

Publication Number Publication Date
WO2006030439A2 WO2006030439A2 (fr) 2006-03-23
WO2006030439A3 true WO2006030439A3 (fr) 2007-05-18

Family

ID=35985262

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IL2005/000991 WO2006030439A2 (fr) 2004-09-17 2005-09-15 Compositions et methodes d'induction de la croissance capillaire
PCT/IL2005/000989 WO2006030437A2 (fr) 2004-09-17 2005-09-15 Nouveaux compose a base de tellure et leurs utilisations
PCT/IL2005/000990 WO2006030438A2 (fr) 2004-09-17 2005-09-15 Utilisation de composes a base de tellure pour inhiber l'enzyme de conversion de l'interleukine

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/IL2005/000989 WO2006030437A2 (fr) 2004-09-17 2005-09-15 Nouveaux compose a base de tellure et leurs utilisations
PCT/IL2005/000990 WO2006030438A2 (fr) 2004-09-17 2005-09-15 Utilisation de composes a base de tellure pour inhiber l'enzyme de conversion de l'interleukine

Country Status (11)

Country Link
US (5) US20090269418A1 (fr)
EP (3) EP1802292A4 (fr)
JP (1) JP2008513439A (fr)
AT (1) ATE402709T1 (fr)
AU (1) AU2005283719A1 (fr)
CA (3) CA2580642C (fr)
DE (1) DE602005008622D1 (fr)
ES (2) ES2312012T3 (fr)
HK (1) HK1103355A1 (fr)
PT (1) PT1796660T (fr)
WO (3) WO2006030439A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060341A2 (fr) 2003-12-18 2005-07-07 Biomas, Ltd Derives du tellure pour la prevention et le traitement des processus neurodegeneratifs
ES2465498T3 (es) * 2004-01-22 2014-06-05 Biomas Ltd. Procedimientos terapéuticos y composiciones farmacéuticas de tratamiento de verrugas con compuestos de teluro
US20080260770A1 (en) * 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
CA2580642C (fr) * 2004-09-17 2014-09-02 Biomas, Ltd. Nouveaux compose a base de tellure et leurs utilisations
US7594717B2 (en) 2005-01-11 2009-09-29 Jemtex Ink Jet Printing Ltd. Inkjet printer and method of controlling same
CA2619073A1 (fr) * 2005-09-15 2007-03-22 Biomas Ltd. Utilisation de composes tellures pour la protection contre le rayonnement ultralviolet
AU2007267069B2 (en) * 2006-06-01 2011-08-11 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP1862166A1 (fr) * 2006-06-01 2007-12-05 Yolanda Rodemer Utilisation de l'allopurinol pour le traitement de l'erythrodysesthesie palmo-plantaire
WO2008032227A2 (fr) * 2006-09-11 2008-03-20 Biomas, Ltd. Formulations topiques de composés contenant du tellure
DK2826371T3 (en) 2007-11-23 2019-04-23 Feramda Ltd Methods and compositions for inhibiting integrins using tellurium-containing compounds
WO2009066301A2 (fr) * 2007-11-23 2009-05-28 Biomas Ltd. Procédés et compositions de traitement de poxvirus au moyen de composés contenant du tellure
WO2010079489A1 (fr) * 2009-01-08 2010-07-15 Biomas Ltd. Composés contenant du tellure pour agir sur le système reproducteur féminin après une chimiothérapie et/ou une radiothérapie
WO2010079488A1 (fr) * 2009-01-08 2010-07-15 Biomas Ltd. Composés contenant du tellurium affectant la fertilité masculine après une chimiothérapie et/ou une radiothérapie
EP2246057A1 (fr) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Utilisation d'allopurinol pour le traitement d'une cutiréaction sur les mains et sur les pieds
WO2010146547A1 (fr) * 2009-06-16 2010-12-23 Biomas Ltd. Composés contenant du tellure destinés à faciliter une transplantation
AU2010300531A1 (en) 2009-09-30 2012-05-24 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2012065065A1 (fr) * 2010-11-12 2012-05-18 Follica, Inc. Procédés et compositions pour moduler la pousse de cheveux, la cicatrisation de plaie et la révision de cicatrice
WO2012078649A1 (fr) 2010-12-06 2012-06-14 Follica, Inc. Procédés destinés à traiter la calvitie et à favoriser la croissance des cheveux
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016221305B2 (en) 2015-02-18 2021-05-27 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107708811B (zh) 2015-04-21 2021-04-30 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
CA3014885A1 (fr) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Association d'une immunotherapie et d'une therapie de controle des cytokines pour le traitement du cancer
US11427538B2 (en) * 2017-04-28 2022-08-30 Kyoto University Organic tellurium compound, method for producing same, living radical polymerization initiator, method for producing vinyl polymer, and vinyl polymer
KR20240033119A (ko) 2017-06-30 2024-03-12 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
CN111295188A (zh) * 2017-09-29 2020-06-16 加利福尼亚大学董事会 调节毛发生长的组合物和方法
JP2021042161A (ja) * 2019-09-11 2021-03-18 国立大学法人東海国立大学機構 脱毛剤、脱毛モデル動物及び白髪モデル動物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262149A (en) * 1992-08-13 1993-11-16 Benjamin Sredni Method of treating or preventing alopecia

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369550A (en) * 1967-02-17 1968-02-20 Thomas A. Armao Cryogenic clamps
GB1427415A (en) 1973-09-21 1976-03-10 Armao T A Cryosurgical instruments
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
US4761490A (en) * 1985-03-15 1988-08-02 Bar-Ilan University Organic derivatives of tellurium and selenium and their use to stimulate cytokine production
US4962207A (en) * 1985-09-30 1990-10-09 Bar-Ilan University Organic derivatives of tellurium and selenium
US5093135A (en) * 1985-09-30 1992-03-03 Michael Albeck Compounds for the induction of in vivo and in vitro production of cytokines
US4752614A (en) * 1985-09-30 1988-06-21 Bar-Ilan University Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4764461A (en) * 1985-09-30 1988-08-16 Bar-Ilan University Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4929739A (en) * 1988-03-24 1990-05-29 Bar-Ilan University Complexes of tellurium and selenium derivatives
US5271925A (en) * 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound
DE4007473A1 (de) 1990-03-09 1991-09-12 Tomsk G Med I Kryoskalpell
US5213899A (en) * 1990-12-17 1993-05-25 General Electric Company Room temperature vulcanizable silicone compositions
EP0778775B1 (fr) 1994-09-01 1999-01-20 PHARMACIA & UPJOHN COMPANY Formulation parenterale de tirilazade avec cosolvant
US5576347A (en) * 1994-11-14 1996-11-19 Sredni; Benjamin Method of treating gastric ulcers
US5654328A (en) 1994-12-15 1997-08-05 Sredni; Benjamin Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
DE69534535T2 (de) 1994-12-15 2006-07-06 Baker Norton Pharmaceuticals, Inc., Miami Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung
RU2274642C2 (ru) * 1998-03-19 2006-04-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы каспаз
US6428534B1 (en) * 1999-02-24 2002-08-06 Cryovascular Systems, Inc. Cryogenic angioplasty catheter
EP1177168B1 (fr) * 1999-04-09 2007-05-30 Cytovia, Inc. Inhibiteurs de la caspase et leur utilisation
TR200200767T1 (tr) * 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
AU7527901A (en) * 2000-06-07 2001-12-17 Vertex Pharma Caspase inhibitors and uses thereof
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
AU2001218024A1 (en) * 2000-06-19 2002-01-02 University Of Southern California Methods for treating and preventing alopecia
ATE359274T1 (de) * 2000-11-21 2007-05-15 Vertex Pharma Imidazol- und benzimidazol- caspase inhibitoren und deren verwendung
US20030148970A1 (en) * 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
EP1392289A2 (fr) * 2001-05-23 2004-03-03 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utilisations
US6472381B1 (en) * 2001-10-12 2002-10-29 Biomas Inc. Method of treating psoriasis
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
AR040350A1 (es) * 2002-06-28 2005-03-30 Vertex Pharma Inhibidores de caspasa y usos de los mismos
TW200500343A (en) * 2002-12-20 2005-01-01 Vertex Pharma Caspase inhibitors and uses thereof
WO2005060341A2 (fr) 2003-12-18 2005-07-07 Biomas, Ltd Derives du tellure pour la prevention et le traitement des processus neurodegeneratifs
WO2006030441A2 (fr) 2004-09-15 2006-03-23 Itamar Medical Ltd. Procede et appareil permettant de mesurer de façon non invasive des parametres physiologiques, notamment le flux sanguin et la capacite veineuse
US20080260770A1 (en) 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
CA2580642C (fr) 2004-09-17 2014-09-02 Biomas, Ltd. Nouveaux compose a base de tellure et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262149A (en) * 1992-08-13 1993-11-16 Benjamin Sredni Method of treating or preventing alopecia
EP0583026A1 (fr) * 1992-08-13 1994-02-16 Benjamin Sredni Méthode pour le traitement de l'alopécie
US6552089B1 (en) * 1992-08-13 2003-04-22 Benjamin Sredni Method of treating or preventing alopecia

Also Published As

Publication number Publication date
AU2005283719A1 (en) 2006-03-23
JP2008513439A (ja) 2008-05-01
EP1791535A2 (fr) 2007-06-06
CA2580643C (fr) 2018-06-12
HK1103355A1 (en) 2007-12-21
US20070298124A1 (en) 2007-12-27
WO2006030437A3 (fr) 2006-06-22
US20100081623A1 (en) 2010-04-01
EP1796660B1 (fr) 2016-11-23
EP1796660A4 (fr) 2008-01-16
PT1796660T (pt) 2017-02-13
EP1796660A2 (fr) 2007-06-20
ES2614113T3 (es) 2017-05-29
US20090269418A1 (en) 2009-10-29
WO2006030438A2 (fr) 2006-03-23
EP1802292A2 (fr) 2007-07-04
US7709524B2 (en) 2010-05-04
CA2580804A1 (fr) 2006-03-23
CA2580642C (fr) 2014-09-02
US8623908B2 (en) 2014-01-07
US7652065B2 (en) 2010-01-26
ATE402709T1 (de) 2008-08-15
CA2580642A1 (fr) 2006-03-23
WO2006030439A2 (fr) 2006-03-23
EP1802292A4 (fr) 2008-02-13
EP1791535B1 (fr) 2008-07-30
ES2312012T3 (es) 2009-02-16
US20080015175A1 (en) 2008-01-17
DE602005008622D1 (de) 2008-09-11
WO2006030438A3 (fr) 2006-05-04
WO2006030437A2 (fr) 2006-03-23
US20100233294A1 (en) 2010-09-16
CA2580643A1 (fr) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2006030439A3 (fr) Compositions et methodes d'induction de la croissance capillaire
IL232313A (en) Modulators of indoleamine 2,3-dioxigenase and methods of use of the above
EP1893216A4 (fr) Methodes et preparations pour le traitement de troubles oculaires
AU2006224295A8 (en) N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
WO2006086562A3 (fr) Derives de phenylazetidinone
ZA201201391B (en) Methods, compositions, and kits for the treatment of medical conditions
WO2005048948A3 (fr) Derives d'uree en tant que modulateurs de la kinase
IL172621A0 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006038923A3 (fr) Imidazonaphthyridines substituees par aryle
EP1727530A4 (fr) Formulations topiques pour le traitement d'etats dermatologiques
WO2005023185A3 (fr) Compositions pharmaceutiques et procede d'utilisation de la levodopa et de la carbidopa
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
IL187405A0 (en) Methods and compositions for the treatment of pain
MY135829A (en) Analeptic and drug combinations
WO2006020430A8 (fr) Nouvelle composition et procedes destines au traitement d'une maladie immunitaire
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
WO2006002203A8 (fr) Methodes et compositions servant au traitement de maladies polykystiques
SG144942A1 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005107464A3 (fr) Composes et compositions utilises en tant qu'inhibiteurs de la cathepsine
WO2004096848A8 (fr) Nouvelle composition et nouvelles methodes de traitement de troubles immunitaires
AU2003202255A1 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
ZA200710476B (en) Methods and compositions for the treatment of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11662743

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2580804

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007531953

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005784166

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005283719

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 554380

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2005283719

Country of ref document: AU

Date of ref document: 20050915

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005283719

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005784166

Country of ref document: EP